07:00 , May 18, 2009 |  BC Week In Review  |  Company News

Kyowa Hakko Kirin, sanofi-aventis deal

Kyowa granted sanofi-aventis exclusive, worldwide rights to develop a human mAb against tumor necrosis factor ligand superfamily member 14 ( TNFSF14, LIGHT, CD258), except in Asia where the companies will co-develop the product....
01:12 , May 15, 2009 |  BC Extra  |  Company News

sanofi-aventis licenses Kyowa mAb

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize a human mAb against tumor necrosis factor ligand superfamily member 14 ( TNFSF14, LIGHT, CD258), except in...